How much has Moderna raised?
Moderna is not venture-backed. As of June 2026 it was a public company trading as Nasdaq: MRNA, with $1.944B 2025 of 2025 revenue scale and mature access to public-company financing tools.
- Public status
- Nasdaq: MRNA
- Revenue
- $1.944B 2025
- Funding type
- Public markets
- Disclosed rounds
- Not VC disclosed
- First raised
- Public-company history
- Seller signal
- Enterprise healthcare buyer
Moderna's capital history
Moderna's capital history is public-company funding, operating cash flow, acquisitions, and market access rather than startup rounds.
- 2010Company foundedModerna begins the business that later scales into a public healthcare company.
- Public listingNasdaq: MRNA public-market accessPublic equity and debt-market access replace startup-style venture rounds as the relevant capital lens.
- Portfolio eraPortfolio expansionAcquisitions, divestitures, internal R&D, and manufacturing investments become important capital-allocation tools.
- 2025$1.944B 2025 revenue scaleModerna's annual revenue for 2025 was approximately $1.944 billion, and Q1 2026 revenue was $389 million as respiratory-vaccine demand remained seasonal.
- Jun 2026Nasdaq: MRNA public companyModerna remains a public enterprise healthcare buyer with mature procurement controls.
How much has Moderna raised in total?
Moderna does not have a meaningful current venture-funding total. The company should be evaluated through public equity, operating cash flow, debt capacity, acquisitions, divestitures, partnerships, and retained earnings rather than Seed, Series A, or late-stage venture rounds.
Who are Moderna's investors?
The relevant investors are public-market shareholders, index funds, active healthcare investors, bondholders where applicable, and internal capital allocators. Their focus is durable revenue, margins, cash conversion, pipeline or product execution, regulatory risk, reimbursement exposure, and management's ability to deploy capital at attractive returns.
Why does Moderna's valuation move?
Moderna's valuation moves with growth, margins, cash flow, clinical or regulatory milestones, procedure or prescription trends, test volume, reimbursement, pricing pressure, product cycles, supply reliability, litigation, acquisitions, and investor confidence in management's outlook. Healthcare buyers can still spend during turbulent markets, but approvals become more tied to measurable savings and risk control.
Is Moderna profitable, and will it IPO?
Moderna is already public. Profitability should be assessed from its filings and earnings releases rather than IPO readiness; the practical question is how much cash and management attention can be allocated to new vendors, systems, facilities, clinical programs, commercial expansion, or productivity work.
What does Moderna's funding mean if you sell into them?
The company has enterprise-scale budget capacity, but procurement is mature and evidence-driven. Sellers should expect security review, compliance review, legal negotiation, business-unit sponsorship, and a requirement to prove value in patient outcomes, operating efficiency, revenue capture, supply reliability, cybersecurity, data quality, or risk reduction.
As of June 2026.Sources:Moderna 2025 resultsModerna annual reportsNasdaq: MRNA market data
Moderna — frequently asked questions
